Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02083822
Other study ID # PHRN11-ES / EPIRMEX
Secondary ID
Status Active, not recruiting
Phase N/A
First received December 13, 2013
Last updated September 18, 2014
Start date June 2011
Est. completion date September 2017

Study information

Verified date September 2014
Source University Hospital, Tours
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

The survival of premature babies increased during the last decades. However, the neurocognitive long term development of these children is worrying, as demonstrated by EPIPAGE 1 study.

These children present high risk of deficits such as cognitive deficits, adaptive malfunction, behavior disorders and difficulties in school learning.

Understanding the specific neuropsychological disorders at the origin of these deficits is an important objective. Studies realized at school age showed that many premature children have executive functions (EF) disorders. However the specific nature of these disorders and the neuropathology associated are unknown.

The aim of this study is to realise MRI at term age in preterm babies born less than 32 GA and to correlate MRI findings with executives functions and neurodevelopmental outcome


Description:

An MRI would be realized between 39 and 41 GA

At the age of 5 years, executive functions and neurodevelopmental testing would be realized.

600 newborns were recruited.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 600
Est. completion date September 2017
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender Both
Age group 25 Weeks to 32 Weeks
Eligibility Inclusion Criteria

Infants who were :

- born between 25 and 32 WGA

- hospitalized in a neonatology service which participate to the present study

- included in EPIPAGE 2 follow-up study

- infants whose parents had signed the consent agreement and benefit from national health insurance

Exclusion Criteria

- Infants with congenital abnormalities

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
term MRI, executive EF functions testing
An MRI will be realized at term born between 25 and 32 weeks GA

Locations

Country Name City State
France Service de Neurologie Pédiatrique Angers
France Service de Néonatologie Bordeaux
France Service de Néonatologie Caen
France Médecine Néonatale et Réanimation Pédiatrique Grenoble
France Service de REANIMATION NEONATALE ET PEDIATRIQUE, NEONATOLOGIE Kremlin Bicêtre
France Service de Néonatologie Lille
France Médecine Infantile - Néonatologie - Périnatologie Marseille
France Service de Néonatalogie Marseille
France Service de Néonatologie Nancy
France Service de Néonatologie Nantes
France Réanimation néonatale et Néonatologie Paris
France Service de Réanimation, Néonatologie Reims
France Service de Néonatologie Rennes
France Service de Pédiatrie Néonatale et Réanimation Rouen
France Service de Réanimation pédiatrique, Néonatologie Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Tours

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Executive functions evaluation at age of 5 and comparison with conventionnal and advanced MRI imagings During the 5 years follow up No
Secondary Perinatal risk factors and cerebral lesions as assessed on MRI During the 5 years follow up No
Secondary Perinatal risk factors and executive and cognitive functions evaluated at 5 years of age During the 5 years follow up No